Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B).
James Chih-Hsin YangYuichiro OheChao-Hua ChiuXiaoling OuMireille CantariniPasi A JanneRyan J HartmaierMyung-Ju AhnPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
In this small study, AEs and tolerability of osimertinib plus selumetinib were as expected, on the basis of previous studies. The combination demonstrated antitumor activity supportive of further investigation in patients with MET-negative, EGFRm advanced NSCLC who had progressed on a previous EGFR-TKI.
Keyphrases
- small cell lung cancer
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- open label
- phase iii
- phase ii
- clinical trial
- brain metastases
- study protocol
- randomized controlled trial
- double blind
- phase ii study
- squamous cell carcinoma
- cross sectional
- rectal cancer
- chronic myeloid leukemia